Bilateral Symmetric Thalamic Metastasis in a Patient with Small Cell Lung Cancer
Journal Title: Cancer Studies & Molecular Medicine – Open Journal - Year 2018, Vol 4, Issue 1
Abstract
A 68-year old woman was referred to our hospital because of dry cough with persistent numbness in the extremities. Chest roentgenogram showed right hilar tumor with mediastinal lymphnode and brain magnetic resonance imaging (MRI) revealed multiple tiny nodules. After performing the transbronchial needle aspiration obtained from subcarinal lymphnode, she was diagnosed with small cell lung cancer (SCLC) accompanied by multiple brain metastasis (clinical stage IV: T4N3M1). After completion of four cycles of chemotherapy, the size of lung lesion was regressed together with complete resolution of brain lesions, and she discharged uneventfully. However, her numbness was remained. Four months later, she was hospitalized again for severe numbness in her trunk and extremities. Brain MRI (contrast-enhanced T1-weighted image) demonstrated new symmetric metastatic lesions in bilateral thalamus (Figure A and B) as well as left putamen. Another two months later, numbness exacerbated and spread from the top to toe with the growing of primary and bilateral thalamic metastatic lesions on computed tomography (CT) (Figure C and D). In spite of whole-brain irradiation, she had suffered from severe numbness, and died of obstructive pneumonia. To our knowledge, this is the first case of bilateral symmetric thalamic metastasis in SCLC with refractory numbness over the whole body.
Authors and Affiliations
Takeshi Saraya
Keywords
Related Articles
- EP ID EP559118
- DOI 10.17140/CSMMOJ-4-123
- Views 118
- Downloads 0
Dosimetric Characterization of an Abscopal Response in a Patient With Oligometastatic Melanoma Undergoing Concurrent Treatment With Pembrolizumab and Stereotactic Body Radiotherapy (SBRT)
Recently, preclinical and clinical evidence has shown that a synergy may exist between radiation and immune check-point therapies such as pembrolizumab. Radiation has been shown to activate the immune system, and in comb...
Skin Hypopigmentation in a Patient with Papillary Carcinoma Thyroid Treated with Sorafenib
Sorafenib is an oral multikinase inhibitor approved for the treatment of advanced renal cell carcinoma, hepatocellular carcinoma and thyroid cancer. The dermatological side effects of sorafenib include palmar-plantar ery...
Treatment of Stage I Seminoma
Stage I testicular seminoma is a curable condition. The primary treatment is high inguinal orchiectomy. The treatment options after surgery includes radiotherapy, chemotherapy with single agent carboplatin and active sur...
Long Term, Low Dose Genistein decreases Stem Cell Populations and Sensitizes Inflammatory Breast Cancer Cell Lines to Radiation
Local recurrence in inflammatory breast cancer is common and is associated with poor prognosis. Recurrence is driven by a small population of radioresistant breast cancer cells that have stem-like properties. Previous st...
Prostate Cancer Trends in Developing Countries
Prostate cancer is the commonest cancer in USA and most European Countries and is the 2nd commonest cancer among males globally. An estimated 1.1 million men worldwide were diagnosed with prostate cancer in 2012, account...